ENTX
insider transactionsEntera Bio Ltd. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Chief Operating Officer
$0
73.0K sh
Own +81%
-
Grant·A
Chief Financial Officer
$0
58.4K sh
Own +52%
-
Grant·A
Chief of R&D
$0
87.6K sh
Own +86%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 7, 2026 | Hillel Galitzer | Grant A | 73.0K | $0 |
| May 7, 2026 | Dana Yaacov-Garbeli KEY | Grant A | 58.4K | $0 |
| May 7, 2026 | Gregory Burshtein | Grant A | 87.6K | $0 |
About ENTX insider trading
This page tracks insider transactions for Entera Bio Ltd. (ENTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.